Fig. 2From: Preventing major adverse cardiovascular events by SGLT-2 inhibition in patients with type 2 diabetes: the role of kidneyRandom-effect meta-analysis describing the effect of the four CVOTs with gliflozins on the primary endpoint (MACE) according to the renal function of patients with T2DBack to article page